JP2020512298A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512298A5 JP2020512298A5 JP2019535356A JP2019535356A JP2020512298A5 JP 2020512298 A5 JP2020512298 A5 JP 2020512298A5 JP 2019535356 A JP2019535356 A JP 2019535356A JP 2019535356 A JP2019535356 A JP 2019535356A JP 2020512298 A5 JP2020512298 A5 JP 2020512298A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally
- disease
- pharmaceutical composition
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*1(C2)[C@]2CN(C)CC1 Chemical compound C*1(C2)[C@]2CN(C)CC1 0.000 description 2
- VWSLLSXLURJCDF-UHFFFAOYSA-N CC1=NCCN1 Chemical compound CC1=NCCN1 VWSLLSXLURJCDF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440581P | 2016-12-30 | 2016-12-30 | |
| US62/440,581 | 2016-12-30 | ||
| PCT/US2017/068636 WO2018125961A1 (en) | 2016-12-30 | 2017-12-28 | Poly-adp ribose polymerase (parp) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512298A JP2020512298A (ja) | 2020-04-23 |
| JP2020512298A5 true JP2020512298A5 (enExample) | 2022-04-19 |
| JP7141399B2 JP7141399B2 (ja) | 2022-09-22 |
Family
ID=61007849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535356A Active JP7141399B2 (ja) | 2016-12-30 | 2017-12-28 | ポリ－ａｄｐリボースポリメラーゼ（ｐａｒｐ）阻害剤 |
Country Status (33)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016333963C1 (en) * | 2015-10-07 | 2021-05-27 | The Salk Institute For Biological Studies | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| PT3562822T (pt) * | 2016-12-30 | 2021-06-02 | Mitobridge Inc | Inibidores de poli-adp ribose polimerase (parp) |
| JP7512380B2 (ja) * | 2019-10-30 | 2024-07-08 | ディグムバイオ．インコーポレイテッド | イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ（ａｄｐ－リボース）ポリメラーゼ－１（ｐａｒｐ－１）関連疾患の予防又は治療用薬学的組成物 |
| WO2022222921A1 (zh) * | 2021-04-22 | 2022-10-27 | 微境生物医药科技(上海)有限公司 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
| KR20240057402A (ko) * | 2021-07-23 | 2024-05-02 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 그람 음성 박테리아 유출 펌프 억제제 |
| CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
| KR20250065924A (ko) | 2022-09-19 | 2025-05-13 | 바스프 에스이 | 아졸 살충 화합물 |
| EP4617262A1 (en) | 2022-11-07 | 2025-09-17 | Kyoto University | Nitrogen-containing heterocyclic compound |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| WO2024240108A1 (zh) * | 2023-05-19 | 2024-11-28 | 上海海和药物研究开发股份有限公司 | 一种芳基脲类parp1抑制剂、其制备方法及用途 |
| CN117024357B (zh) * | 2023-07-03 | 2026-02-24 | 山东第二医科大学 | 一种针对brca突变的选择性抑制剂及其用途 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN118084678B (zh) * | 2024-03-01 | 2024-09-06 | 长沙唯楚医药科技有限公司 | 一种2-溴-6-氟苯胺的制备方法 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202608867A (zh) * | 2024-04-26 | 2026-03-01 | 美商雷密克斯醫療公司 | 用於降解週期蛋白k及抑制週期蛋白依賴性激酶之化合物及相關方法 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026030819A1 (en) * | 2024-08-08 | 2026-02-12 | Waverley Pharma Inc. | Substituted (3-hydroquinazolin-4-one) derivatives and pharmaceutical compositions thereof use as potent & selective poly [adp ribose] polymerase 1(p arp-1) inhibitors for the treatment of cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001249262A1 (en) | 2000-03-20 | 2001-10-03 | Sepracor, Inc. | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| EP1272187B1 (de) | 2000-03-27 | 2008-07-30 | Abbott GmbH & Co. KG | Dopamin-d3-rezeptor-liganden zur behandlung von sucht |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| CA2568835C (en) * | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| CN101263125A (zh) | 2005-07-15 | 2008-09-10 | 先灵公司 | 用于癌症治疗的喹唑啉衍生物 |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| WO2007110868A2 (en) | 2006-03-28 | 2007-10-04 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2012140642A1 (en) | 2011-04-10 | 2012-10-18 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| EP2890696A1 (en) * | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| SG11201600743WA (en) | 2013-07-31 | 2016-02-26 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
| RU2016147727A (ru) | 2014-05-07 | 2018-06-08 | Мерк Патент Гмбх | Гетероциклилбутанамидные производные |
| CN105924434A (zh) * | 2015-02-28 | 2016-09-07 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
| PT3562822T (pt) * | 2016-12-30 | 2021-06-02 | Mitobridge Inc | Inibidores de poli-adp ribose polimerase (parp) |
-
2017
- 2017-12-28 PT PT178326948T patent/PT3562822T/pt unknown
- 2017-12-28 US US16/473,127 patent/US11034670B2/en active Active
- 2017-12-28 RS RS20210653A patent/RS61895B1/sr unknown
- 2017-12-28 EP EP17832694.8A patent/EP3562822B1/en active Active
- 2017-12-28 LT LTEP17832694.8T patent/LT3562822T/lt unknown
- 2017-12-28 JP JP2019535356A patent/JP7141399B2/ja active Active
- 2017-12-28 ES ES17832694T patent/ES2875841T3/es active Active
- 2017-12-28 CN CN201780082024.8A patent/CN110167926B/zh active Active
- 2017-12-28 JO JOP/2019/0115A patent/JOP20190115B1/ar active
- 2017-12-28 CA CA3047137A patent/CA3047137A1/en active Pending
- 2017-12-28 MX MX2019007870A patent/MX393606B/es unknown
- 2017-12-28 KR KR1020197021891A patent/KR102606799B1/ko active Active
- 2017-12-28 EA EA201991412A patent/EA201991412A1/ru unknown
- 2017-12-28 SM SM20210321T patent/SMT202100321T1/it unknown
- 2017-12-28 MA MA47165A patent/MA47165B1/fr unknown
- 2017-12-28 DK DK17832694.8T patent/DK3562822T3/da active
- 2017-12-28 PL PL17832694T patent/PL3562822T3/pl unknown
- 2017-12-28 MD MDE20191268T patent/MD3562822T2/ro unknown
- 2017-12-28 UA UAA201908940A patent/UA124777C2/uk unknown
- 2017-12-28 HU HUE17832694A patent/HUE054382T2/hu unknown
- 2017-12-28 WO PCT/US2017/068636 patent/WO2018125961A1/en not_active Ceased
- 2017-12-28 HR HRP20210887TT patent/HRP20210887T1/hr unknown
- 2017-12-28 AU AU2017388376A patent/AU2017388376B2/en active Active
- 2017-12-28 MY MYPI2019003419A patent/MY199045A/en unknown
- 2017-12-28 SI SI201730772T patent/SI3562822T1/sl unknown
- 2017-12-29 AR ARP170103718A patent/AR110706A1/es active IP Right Grant
- 2017-12-29 TW TW106146555A patent/TWI773718B/zh active
-
2019
- 2019-05-29 SA SA519401894A patent/SA519401894B1/ar unknown
- 2019-06-20 ZA ZA2019/04004A patent/ZA201904004B/en unknown
- 2019-06-26 IL IL267676A patent/IL267676B/en unknown
- 2019-06-28 PH PH12019501529A patent/PH12019501529A1/en unknown
- 2019-07-23 CO CONC2019/0007906A patent/CO2019007906A2/es unknown
-
2020
- 2020-06-03 ZA ZA2020/03310A patent/ZA202003310B/en unknown
-
2021
- 2021-06-08 CY CY20211100500T patent/CY1124565T1/el unknown
- 2021-06-09 US US17/342,873 patent/US11993585B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018137521A (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
| HRP20210887T1 (hr) | Inhibitori poli-adp riboza polimeraze (parp) | |
| JP2019511527A5 (enExample) | ||
| RU2019110736A (ru) | Кристаллические и солевые формы соединений агонистов ppar | |
| US20240409487A1 (en) | Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases | |
| JP2013516501A5 (enExample) | ||
| US10968172B2 (en) | USP30 inhibitors | |
| JP2021501786A5 (enExample) | ||
| AU2005260821B2 (en) | Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor | |
| JP2018508569A5 (enExample) | ||
| WO2010115836A4 (en) | Substituted piperidines as ccr3 antagonists | |
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2021501787A5 (enExample) | ||
| JP2018522042A5 (enExample) | ||
| JP2023529570A5 (enExample) | ||
| JP2023527025A5 (enExample) | ||
| BR112014020992B1 (pt) | Composto,uso de composto na fabricação de um medicamento e composição farmacêutica | |
| ZA200502084B (en) | Pyridine derivatives as CB2 receptor modulators. | |
| JP2017534665A5 (enExample) | ||
| JP2011520836A (ja) | 代謝性障害を治療するのに有用なサリチレートコンジュゲート | |
| JP2015517514A5 (enExample) | ||
| JP2021518347A (ja) | ペルオキシソーム増殖因子活性化受容体アルファのアゴニストおよび使用方法 | |
| RU2020124097A (ru) | НИЗКОМОЛЕКУЛЯРНЫЕ МОДУЛЯТОРЫ ДОМЕНА BTB Keap1 | |
| CN112759559B (zh) | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 | |
| TW202133842A (zh) | Iap抑制劑與parp或mek抑制劑或其他化學治療劑的組合 |